Acadia Pharma loses $85.3 million in first quarter

Acadia Pharma loses $85.3 million in first quarter

Play Episode Pause Episode

Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds

00:00 /

RSS Feed

Share

Link

Embed

However, sales of flagship drug Nuplazid — the only FDA-approved treatment for Parkinson’s disease psychosis — increase